Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R1); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C5-C10aryl, substituted or unsubstituted hetero-C5-C10aryl, a group N(R1)(R4), or a group N(R2)(CHP3R4); R represent a hydrogen, C1-C4alkyl, or CF3; R2 represents hydrogen, C1-C4alkyl, or CF3; R3 represents hydrogen, C1-C4alkyl, or CF3; R4 represents a substituted or unsubstituted C5-C10 aryl or a substituted or unsubstituted C5-C10heteroaryl; in free base or acid addition salt form.

Abstract: A method of producing a progressive spectacle glass by defining an ordering value for the average use value in the far reference point of the progressive spectacle glass, calculating the progressive spectacle glass while taking into account a calculation value of the average use value in the far reference point, the calculation value having a negative desired refraction deviation between 0.03 dpt and 0.2 dpt with respect to the ordering value in the far reference point, and producing the calculated progressive spectacle glass.

Abstract: A method for automatic sleeve filling of a winding shaft on roll cutting and winding machines is provided in which, in an exemplified embodiment, in a first step at least two empty winding sleeves are slid onto a free end of a winding shaft so that the winding sleeves are adjacent to one another, in a second step the last winding sleeve slid on by a freely positionable fork piece of a freely programmable draw-off plate along the winding shaft is slid over the winding shaft until the last winding sleeve has reached a predetermined position, in a third step the next-to-last winding sleeve slid on is grasped by tongs freely positionable along the winding shaft and is slid over the winding shaft to the point where in a fourth step the fork piece can dip into the gap produced by the tongs so that the next-to-last winding sleeve is positionable along the winding shaft by the fork piece.

Abstract: The present invention relates to the use of cyclic peptides, in particular of vioprolides for the treatment and prevention of various diseases, disorders and conditions. In particular, the present invention provides compounds useful in enhancing and/or supporting interferon type I1 like interferon alpha or interferon beta, treatment or prevention of diseases, disorders or conditions. Further, the present invention relates to new pharmaceutical compositions comprising specific cyclic peptides, in particular, vioprolides, and type I interferon and its use in the treatment of various diseases, in particular, in the treatment or prevention of infectious diseases, cancers etc. Finally, the present invention provides methods for preventing or treating diseases, disorders or conditions susceptible to type I interferon treatment or prevention.

Abstract: Use of a protein of the SDF-1-family for the manufacturing of a medicament for the improvement of the plasticity and/or regeneration of axons upon their lesion.

Abstract: A device for the reduction of nitrogen oxides in the exhaust gas of internal combustion engines has a thermolysis reactor (10). In the thermolysis reactor (10), urea is converted into ammonia and isocyanic acid by means of the supply of heat. In a preferred embodiment of the invention, the thermolysis reactor (10) is arranged within the exhaust gas duct (26) and is thermally coupled to an oxidation catalytic converter (30) which is connected upstream of the thermolysis reactor (10) in the flow direction. As a result of the exothermic reactions taking place in the oxidation catalytic converter (30), it is possible for heating of the thermolysis reactor (10) to take place. In order to further increase the temperature, it is possible for fuel to be injected into the oxidation reactor (30) by means of a fuel supply device. The fuel is burned catalytically in the oxidation catalytic converter (30).

Abstract: A module for a tester for the testing of circuit boards is described. Such testers have a basic grid on which an adapter and/or a translator may be arranged in order to connect contact points of the basic grid with circuit board test points of a circuit board to be tested. The module comprises a support plate and a contact board. The contact board is formed by a rigid circuit board section which is described as the basic grid element, and at least one flexible circuit board section. Provided on the basic grid element are contact points which each form part of the contact points of the basic grid. The basic grid element is mounted at an end face of the support plate, and the flexible circuit board section is bent in such a way that at least part of the other section of the contact board is parallel to the support plate.

Abstract: A method for automatic sleeve filling of a winding shaft on roll cutting and winding machines is provided in which, in an exemplified embodiment, in a first step at least two empty winding sleeves are slid onto a free end of a winding shaft so that the winding sleeves are adjacent to one another, in a second step the last winding sleeve slid on by a freely positionable fork piece of a freely programmable draw-off plate along the winding shaft is slid over the winding shaft until the last winding sleeve has reached a predetermined position, in a third step the next-to-last winding sleeve slid on is grasped by tongs freely positionable along the winding shaft and is slid over the winding shaft to the point where in a fourth step the fork piece can dip into the gap produced by the tongs so that the next-to-last winding sleeve is positionable along the winding shaft by the fork piece.

Abstract: The invention concerns a nucleic acid molecule which includes a nucleic acid sequence coding for a chemokine, a neuropeptide precursor or at least one neuropeptide, as well as a host cell which contains this nucleic acid molecule. In addition the invention concerns a polypeptide molecule which functions as chemokine or neuropeptide or contains at least one neuropeptide, as well as fragments thereof which include at least one neuropeptide, and a procedure for the manufacture of the polypeptide molecule or of a fragment thereof. In addition the invention concerns antibodies, demonstration procedures and test-kits as well as pharmaceutical preparations. The purpose on which present invention is based is to make new means available which can be put to use aimed at the diagnosis and/or treatment of diseases which are associated with a defect of the SDF-1 factor or its receptor (CXCR4).

Abstract: The invention relates to a method for the production of a eukaryotic cell selectable by inactivation or reduction of an endogenous gene function, comprising the steps of (a) introduction of one or more vectors into the cell and (b) expression of a siRNA and preferably shRNA coded by the one or more vectors, directed against an endogenous selectable gene and inactivating same, said siRNA or shRNA being the transcription product of an RNAi selection cassette, the selection cassette comprising a section of at least 19 nucleotides of the transcribed region of the gene, said selection being operatively linked to a promoter and a transcription termination signal.

Abstract: The present invention relates to the use of recombinant silicatein-? or silicatein-? isolated from natural sources as well as to silicatein-?-fusion proteins as well as silicatein-?-related enzymes for the synthesis, the degradation and for modification of silicon dioxide (condensation products of silicic acid, silicates), silicones and other silicon(IV)- or metal(IV)-compounds, and their technical uses.

Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R1); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C5-C10aryl, substituted or unsubstituted hetero-C5-C10aryl, a group N(R1)(R4), or a group N(R2)(CHP3R4); R represent a hydrogen, C1-C4alkyl, or CF3; R2 represents hydrogen, C1-C4alkyl, or CF3; R3 represents hydrogen, C1-C4alkyl, or CF3; R4 represents a substituted or unsubstituted C5-C10 aryl or a substituted or unsubstituted C5-C10heteroaryl; in free base or acid addition salt form.

Abstract: Silicatein is an enzyme of silicate-forming organisms used for the synthesis of their silicate scaffold. The present invention relates to the use of highly-expressed and highly active recombinant silicatein, silicatein isolated from natural sources after gene induction as well as silicatein-fusion proteins for the synthesis of amorphous silicon dioxide (silicic acids and silicates), siloxanes as well as modification of these compounds and their technical use.

Abstract: The invention relates to compounds of formula (I) Wherein R1, R2, R3, R4 and n are as defined in the specification, to processes for their manufacture, to their use as pharmaceuticals, in diagnosis, as PET ligands and to pharmaceutical or diagnostic compositions comprising such compounds.

Abstract: A method of producing a progressive spectacle glass by defining an ordering value for the average use value in the far reference point of the progressive spectacle glass, calculating the progressive spectacle glass while taking into account a calculation value of the average use value in the far reference point, the calculation value having a negative desired refraction deviation between 0.03 dpt and 0.2 dpt with respect to the ordering value in the far reference point, and producing the calculated progressive spectacle glass.

Abstract: A method for the improvement of neuronal regeneration by prevention or inhibition of basal membrane formation induced by a lesion of neuronal tissue.

Abstract: An exhaust gas device to control, respectively regulates the torque, respectively the performance/power output of a combustion engine includes at least one primary and one secondary flow routing, for gases coming from the combustion engine. The flow routings are designed, to optimize the torque and or the performance/power output of the combustion engine, depending on existing operating parameters. A control element to control respectively regulate the exhaust gas through at least one flow routing.

Abstract: The compounds sorbicillacton A and sorbicillacton-A-derivatives of the general formula I are described, as well as methods for their production. Sorbicillacton A and sorbicillacton-A-derivatives, in cellular culture models, exhibit antitumour- and antiviral properties. Furthermore, sorbicillacton A has inflammation inhibiting properties. Finally, the synthesis of sorbicillacton A and its derivatives is described.

Abstract: Silicatein is an enzyme of silicate-forming organisms used for the synthesis of their silicate scaffold. The present invention relates to the use of highly-expressed and highly active recombinant silicatein, silicatein isolated from natural sources after gene induction as well as silicatein-fusion proteins for the synthesis of amorphous silicon dioxide (silicic acids and silicates), siloxanes as well as modification of these compounds and their technical use.

Abstract: A method is provided for producing ammonia (NH3) and introducing the produced ammonia (NH3) into an exhaust gas stream as a reduction means for selectively catalytically reducing nitrogen oxides contained in the exhaust gas stream, which is an exhaust stream generated by the combustion process of a motor, a gas turbine, or a burner. The method comprises feeding dry urea from a supply container in a controlled amount to reactor and subjecting the dry urea in the reactor to a sufficiently rapid thermal treatment such that a gas mixture comprising the reaction products of ammonia (NH3) and isocyanic acid (HCNO) is created. Also, the method comprises immediately catalytically treating the thus produced gas mixture in the presence of water such that the isocyanic acid (HCNO) resulting from the rapid thermal treatment is converted, via quantitative hydrolysis treatment, into ammonia (NH3) and carbon dioxide (CO2).